Related references
Note: Only part of the references are listed.Mechanisms behind the non-thyroidal illness syndrome: an update
Maria H. Warner et al.
JOURNAL OF ENDOCRINOLOGY (2010)
Iodine-131-Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hepatic absorbed radiation dosimetry during I-131 Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma
Kenneth F. Koral et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
Steven G. DuBois et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Transient sialoadenitis:: A complication of 131I-Metaiodobenzylguanidine therapy
Shakeel Modak et al.
PEDIATRIC BLOOD & CANCER (2008)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cumulative incidence in competing risks data and competing risks regression analysis
Haesook T. Kim
CLINICAL CANCER RESEARCH (2007)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Endocrine late effects from multi-modality treatment of neuroblastoma
HM van Santen et al.
EUROPEAN JOURNAL OF CANCER (2005)
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma
MN Gaze et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
SG DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma
HM van Santen et al.
CANCER (2003)
Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma
B Weiss et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence
S Acharya et al.
CANCER (2003)
Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine
A Garaventa et al.
CANCER (2003)
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma
GA Yanik et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during 131I-meta-iodobenzylguanidine treatment in children with neuroblastoma
HM van Santen et al.
CANCER (2002)
Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: Influence of potassium iodide for thyroid blocking
B Brans et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2002)
Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
S Mastrangelo et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
